Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization

British Journal of Cancer

Volumn 79, Issue 1, 1999, Pages 131-137

  Okamoto, I ^a   Pirc Danoewinata, H ^a   Ackermann, J ^a   Drach, J ^a   Schlagbauer Wadl, H ^a   Jansen, B ^a   Wolff, K ^a   Pehamberger, H ^a   Marosi, C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytogenetics; Deletion; Fluorescence in situ hybridization; Immunohistochemistry; Melanoma; p53

Indexed keywords

PROTEIN P53;

ADVANCED CANCER; ARTICLE; CENTROMERE; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL ARTICLE; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MELANOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032889231     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690022     Document Type: Article

References (35)

1. Akslen LA and Morkve O (1992) Expression of p53 protein in cutaneous melanoma. Int J Cancer 52: 13-16
2. Balch CM, Houghton AN, Milton GW, Sober AJ and Soong SJ (1992) Cutaneous Melanoma, 2nd edn. JB Lippincott: Grand Rapids, New York
3. Cannan-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade OI, Diaz MO, Kwiatkowsky DJ, Piepkorn MW, Zone JJ and Skolnick MH (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258: 1148-1152
4. Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J and Bird CC (1993) Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8: 1397-1401
5. Catresana JS, Rubio M-P and Vazquez JJ (1993) Lack of allelic deletion and point mutation as mechanism of p53 activation in human malignant melanoma. Int J Cancer 55: 562-565
6. Chen TR and Shaw MW (1973) Stable chromosome changes in a human malignant melanoma. Cancer Res 33: 2042-2047
7. Drach J (1994) Interphasenzytogenetik mittels Fluoreszenz-In-situ-Hybridisierung (FISH) In Methoden der diagnostischen Hämatologie, Huber H, Löffler H, Faber V (eds), pp. 119-124, Springer Verlag: Berlin
8. Drach J, Angerler J, Schuster J, Rothermund C, Thalhammer R, Haas OA, Jäger U, Fiegl M, Geissler K, Ludwig K and Huber H (1995): Interphase fluorescence in situ hydridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86: 3915-3921
9. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE and Dracopoli NC (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89: 10557-10561
10. Frankel RH, Bayona W, Koslow M and Newcomb EW (1992) P53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutations frequency. Cancer Res 52: 1427-1433
11. Gaidano G, Serra A, Guerrasio A, Rege-Cambrin G, Mazza U and Saglio G (1993) Genetic analysis of p53 and RB 1 tumour-suppressor-genes in blast crisis of chronic myeloid leukemia. Ann Haematol 68: 3-7
12. Harris CC (1993) p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1981
13. Heim S, Mandahl N, Arheden K, Giovanella BC, Yim SO, Stehlin Jr JS, Mitelman F (1988) Multiple karyotypic abnormalities, including structural rearrangements of 11p, in cell lines from malignant melanoma. Cancer Genet Cytogenet 35: 5-20
14. Holland EA, Beaton SC, Edwards BG, Kefford RF and Mann GJ (1994) Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene 9: 1361-1365
15. Johnson TM, Smith JW, Nelson BR and Chang A (1995) Continuing medical education: current therapy for cutaneous melanoma. J Am Acad Dermatol 32(5): 689-707
16. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE and Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumour types. Science 264: 436-450
17. Kanoko M, Ueda M, Nagano T and Ichihashi M (1995) Expression of p53 protein in melanoma progression. J Dermatol Sci 12: 97-103
18. Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A and Nowell P (1985) Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somatic Cell Mol Genet 11: 297-302
19. Kuerbitz SJ, Plunkett BB, Walsh WV and Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
20. Lee HM, Abrahamson JJA and Bernstein A (1994) DNA damage, oncogenesis and the p53 tumour-suppressor gene. Mutation Res 307: 573-581
21. Levine AJ (1993) The tumour suppressor genes. Annu Rev Biochem 62: 623-651
22. Lynch HT, Fusaro RM, Sandberg AA, Bixeman HA, Johnsen LR, Lynch JF, Ramesch KH and Leppert M (1993) Chromosome instability and the FAMMM syndrome. Cancer Genet Cytogenet 71: 27-39
23. Mitelman F (1995) An International System for Human Cytogenetic Nomenclature Mitelman F (ed.). S. Karger: Basle
24. Pederson IM, Bennet JW and Wang N (1986) Nonrandom chromosome structural aberrations and oncogene loci in human malignant melanoma. Cancer Genet Cytogenet 20: 11-27
25. Piepkorn MW (1994) Genetic basis of susceptibility to melanoma. J Am Acad Dermatol 31: 1022-1039
26. Pietenpol JA and Vogelstein B (1993) No room at the p53 inn. Nature (London) 365: 17-18
27. Poremba C, Yandell DW, Metze D, Kamanabrou D, Böcker W and Dockhorn-Dworniczak B (1995) Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 7: 331-339
28. Prives C and Manfredi JJ (1993) The p53 tumour suppressor protein: meeting review. Genes Dev 7: 529-534
29. Saez-Santamaría MC, McNutt NS, Bogdany JK and Shea CR (1995) P53 expression is rare in cutaneous melanomas. Am J Dermatopathol 17: 344-349
30. Saylors RL, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B and Brodeur GM (1991) Infrequent p53 gene mutations in medulloblastomas. Cancer Res 51: 4721-4723
31. Schweitzer D and Ambros PF (1994) Chromosome banding: stain combinations for specific regions. In Methods in Molecular Biology, Vol. 29: Chromosome Analysis Protocols, Gosden JR (ed), pp. 97-112. Humana Press: Totowa, NJ
32. Skolnick MH, Cannon-Albright LA and Kamb A (1994) Genetic predisposition to melanoma. Eur J Cancer 30A, 13: 1991-1995
33. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP and Harris AL (1991) Expression of mutant p53 in melanoma. Cancer Res 51: 5976-5979
34. Talve L, Kainu J, Collan Y and Ekfors T (1996) Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometrie in primary malignant melanoma of the skin. Pathol Res Pract 192: 825-833
35. Trent JM, Meyskens FL, Salmon SE, Ryschon K, Leong SP, Davis JR and McGee DL (1990) Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med 322: 1508-1511